KEY INVESTIGATOR. If during the Research Period Xx. Xxxxxx Xxxxx's association with Rigel, in the capacity as chief scientific officer or a similar role ends for any reason and the Parties are unable to agree on a successor acceptable to Pfizer, in its sole and unfettered discretion, within one hundred eighty (180) days of his dissociation, Pfizer may terminate this Agreement pursuant to Section 8.3.1.
Appears in 4 contracts
Samples: Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc), Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc), Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc)
KEY INVESTIGATOR. If during the Research Period Xx. Xxxxxx Xxxxx's association with Rigel, in the capacity as chief scientific officer or a similar role ends for any reason and the Parties are unable to agree on a successor acceptable to Pfizer, in its sole and unfettered discretion, within one hundred eighty (180) days of his dissociation, Pfizer may terminate this Agreement pursuant to Section 8.3.1. 3.
Appears in 1 contract
